FDA approves Ryanodex, new malignant hyperthermia drug
from Anesthesiology News
The FDA has approved Ryanodex for the treatment of malignant hyperthermia, marking the first major development for the life-threatening complication of anesthesia in more than 30 years, according to the manufacturer. The drug, an injectable suspension of dantrolene sodium, will be available in 250 milligram single-use vials containing the active ingredient in a lyophilized powder.
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063